Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s share price was down 1.3% during trading on Thursday following insider selling activity. The stock traded as low as $127.10 and last traded at $127.11, with a volume of 244,383 shares. The stock had previously closed at $128.81.

Specifically, SVP Paul Treacy sold 1,292 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $137.47, for a total transaction of $177,611.24. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $126.17, for a total value of $25,234.00. Following the sale, the senior vice president now owns 17,325 shares in the company, valued at approximately $2,185,895.25. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

JAZZ has been the topic of several recent research reports. Piper Jaffray Cos. restated a “buy” rating and set a $186.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, May 31st. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, July 20th. Leerink Swann restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, May 31st. Mizuho restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Monday, June 6th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $195.00 target price (down previously from $196.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $185.67.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/jazz-pharmaceuticals-plc-jazz-trading-down-1-3-after-insider-selling.html

The stock’s 50 day moving average is $131.65 and its 200-day moving average is $139.67. The firm has a market capitalization of $7.71 billion, a price-to-earnings ratio of 22.40 and a beta of 0.93.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.80 by $0.17. The business had revenue of $381 million for the quarter, compared to analysts’ expectations of $376.40 million. Jazz Pharmaceuticals PLC had a return on equity of 28.39% and a net margin of 25.46%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.41 EPS. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post $10.08 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors boosted its position in shares of Jazz Pharmaceuticals PLC by 3.2% in the first quarter. BlackRock Fund Advisors now owns 1,527,156 shares of the specialty pharmaceutical company’s stock valued at $199,370,000 after buying an additional 47,265 shares in the last quarter. State Street Corp boosted its position in shares of Jazz Pharmaceuticals PLC by 7.7% in the first quarter. State Street Corp now owns 1,333,938 shares of the specialty pharmaceutical company’s stock valued at $174,128,000 after buying an additional 95,849 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Jazz Pharmaceuticals PLC by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 1,233,053 shares of the specialty pharmaceutical company’s stock valued at $174,242,000 after buying an additional 49,967 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals PLC by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 1,074,731 shares of the specialty pharmaceutical company’s stock valued at $140,307,000 after buying an additional 179,454 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Jazz Pharmaceuticals PLC by 2.0% in the second quarter. Prudential Financial Inc. now owns 620,397 shares of the specialty pharmaceutical company’s stock valued at $87,668,000 after buying an additional 12,320 shares in the last quarter. Institutional investors and hedge funds own 88.25% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.